In this IgNS 2024 conference video, Dr. Eleni Tiniakou, a rheumatologist and assistant professor at Johns Hopkins, shares advancements in myositis treatment approaches. She highlights evidence-based therapies, including interferon pathway inhibitors, B-cell targeting, and early research on CAR T-cell applications. Dr. Tiniakou emphasizes the importance of personalized approaches to address the diverse pathogenic factors in myositis treatment. These insights provide physicians tools to better tailor treatments across myositis subtypes and improve patient outcomes.
In this IgNS 2024 conference video, Dr. Eleni Tiniakou, a rheumatologist and assistant professor at Johns Hopkins, shares advancements in myositis treatment approaches. She highlights evidence-based therapies, including interferon pathway inhibitors, B-cell targeting, and early research on CAR T-cell applications. Dr. Tiniakou emphasizes the importance of personalized approaches to address the diverse pathogenic factors in myositis treatment. These insights provide physicians tools to better tailor treatments across myositis subtypes and improve patient outcomes.
Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38117543/
gMG has a physical, mental, and social impact, resulting in a considerable burden of disease and substantially decreased QoL, despite standard treatments. The availability of novel, targeted treatments that influence...
Generalized myasthenia gravis (gMG) presents management challenges; new therapies and standardized assessments can improve patient outcomes, optimize treatment, and enhance quality of life through personalized approaches and novel biomarkers.
Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+) - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39227284/
ADAPT-SC (NCT04735432) was designed to evaluate noninferiority of subcutaneous (SC) efgartigimod PH20 to intravenous (IV) efgartigimod in participants with generalized myasthenia gravis (gMG). ADAPT-SC+ (NCT04818671) is an open-label extension study...
The ADAPT-SC and ADAPT-SC+ studies confirm that subcutaneous efgartigimod PH20 is noninferior to intravenous efgartigimod, demonstrating long-term safety and efficacy in treating generalized myasthenia gravis.
In this video recap of the 2024 AANEM Annual Conference, Dr. Dianna Quan, MD, AANEM President and faculty at the University of Colorado School of Medicine, along with Dr. Donald Sanders, MD, neuromuscular neurologist, and Dr. Massey, MD, neuromuscular specialist from Duke University School of Medicine, discuss pivotal research findings. Key highlights include promising advances in plasma exosomes as biomarkers for diabetic peripheral neuropathy and the application of artificial intelligence in ultrasound imaging to differentiate between neurogenic and myogenic changes. They also review a study comparing the effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis, emphasizing the role of immunosuppressive therapies in treatment planning. Overall, the conference underscored the importance of integrating innovative research and technology to enhance diagnostic and treatment approaches in neuromuscular medicine.
